Otsuka Pharmaceutical Co., Ltd. has announced the successful completion of its acquisition of Transcend Therapeutics, Inc. through its wholly owned subsidiary, Otsuka America, Inc. (OAI).
With the transaction now complete, Transcend has officially become a wholly owned subsidiary of OAI. The acquisition marks another step in Otsuka’s strategy to strengthen its position in the psychiatric and neurological treatment space.
The agreement between the two companies was originally signed in March 2026.
As part of the acquisition, Otsuka paid approximately $700 million to acquire all outstanding shares of Transcend Therapeutics.
In addition to the upfront payment, the agreement includes potential future milestone payments of up to $525 million. These additional payments are tied to future sales performance and development milestones related to Transcend’s pipeline assets.
The structure of the deal reflects Otsuka’s confidence in the long-term potential of Transcend’s drug development programs.
Founded in 2021, Transcend Therapeutics is a clinical-stage biotechnology company focused on developing rapid-acting therapies for neuropsychiatric disorders.
The company’s lead drug candidate, TSND-201 (methylone), is being developed as a potential treatment for post-traumatic stress disorder (PTSD) and other psychiatric conditions.
TSND-201 belongs to a new class of therapies known as neuroplastogens. These therapies are designed to promote rapid and long-lasting neural plasticity, which refers to the brain’s ability to adapt, reorganize, and form new connections.
Researchers believe this approach could help address underlying neurological changes associated with certain mental health disorders.
PTSD Remains an Area of Significant Unmet Need
Post-traumatic stress disorder continues to affect millions of people worldwide.
In the United States alone, more than 13 million people are estimated to live with PTSD each year. Despite the high disease burden, no major new treatment for PTSD has received approval in nearly 25 years.
Many patients continue to struggle with symptoms such as anxiety, flashbacks, emotional distress, sleep disturbances, and difficulties with daily functioning.
The lack of new treatment options has created a significant need for innovative therapies that can provide meaningful improvements for patients.
TSND-201 Shows Positive Phase 2 Results
Transcend's lead program has already produced encouraging clinical data.
TSND-201 demonstrated positive results in the Phase 2 IMPACT-1 clinical trial, which evaluated the treatment in adults living with PTSD.
The findings from the study were published in JAMA Psychiatry in February 2026, providing additional scientific support for the program.
The positive outcomes helped position TSND-201 as one of the more closely watched investigational therapies in the PTSD treatment landscape.
Phase 3 Study Currently Underway
The development of TSND-201 has now advanced into Phase 3 clinical testing.
The ongoing EMPOWER-1 study is the first Phase 3 trial designed to evaluate the safety and effectiveness of TSND-201 in patients with PTSD.
The study is currently being conducted across the United States, with full completion expected around the end of 2027.
Results from this trial will play an important role in determining whether the therapy can move closer to regulatory approval.
FDA Grants Important Regulatory Designations
TSND-201 has already received several important recognitions from the U.S. Food and Drug Administration (FDA).
In July 2025, the FDA granted Breakthrough Therapy Designation to TSND-201. This designation is intended for therapies that may offer substantial improvements over existing treatment options for serious conditions.
In April 2026, the company also received the FDA Commissioner’s National Priority Voucher for TSND-201.
The voucher program is designed to help accelerate the review of therapies that address important national health priorities while maintaining the FDA’s scientific and regulatory standards.
These designations could help support a faster development and review pathway for the investigational treatment.
Otsuka Expands Leadership in Psychiatry and Neurology
Otsuka has built a strong presence in psychiatric and neurological medicine over several decades.
By bringing Transcend into its organization, the company aims to expand its portfolio of innovative therapies and strengthen its leadership position in these therapeutic areas.
The acquisition also gives Otsuka access to Transcend’s scientific expertise and drug development capabilities in emerging neuropsychiatric treatments.
Combining Experience and Innovation
According to Otsuka, the integration of Transcend's innovative research platform with Otsuka’s long-standing experience in psychiatric and neurological diseases could help accelerate the development of next-generation therapies.
The companies plan to work closely with regulatory authorities as they continue advancing TSND-201 and other future treatment candidates.
Their shared goal is to develop new options for patients living with PTSD and other serious psychiatric disorders where treatment needs remain high.